CEO Eric Lefkofsky entities sell 166,250 Tempus AI (TEM) shares under 10b5-1 plan
Entities associated with Tempus AI CEO and Chairman Eric P. Lefkofsky sold a total of 166,250 shares of Class A Common Stock on June 29, 2026. The sales were executed by Blue Media, LLC and Gray Media, LLC at weighted average prices between $54.82 and $59.59 per share, pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2025. Following these transactions, Blue Media, LLC holds 15,514,198 shares and Gray Media, LLC holds 8,806,216 shares, with additional indirect and direct holdings.
Tempus AI CFO James Rogers sells $634,095 in TEM stock By Investing.com
Tempus AI, Inc.'s CFO, James William Rogers, sold 11,529 shares of Class A Common Stock for $634,095, executed under a Rule 10b5-1 trading plan. Despite the sale, Rogers still directly holds 114,866 shares. The company has recently engaged in research collaborations for angiosarcoma and launched a digital pathology open-source consortium, with analysts like Canaccord Genuity reiterating a Buy rating on TEM stock.
Tempus AI director Jennifer Doudna sells $147,015 in stock
Tempus AI director Jennifer Doudna sold 2,673 shares of Class A Common Stock for $147,015 on June 25, 2026, as part of a Rule 10b5-1 trading plan. Post-sale, Doudna retains 25,942 shares, and while the stock has surged, InvestingPro data suggests it is overvalued. Tempus AI has also announced collaborations in angiosarcoma research and digital pathology, alongside a multi-site validation study for its FDA-cleared software, with Canaccord Genuity maintaining a Buy rating.
Tempus AI CFO James Rogers sells $634,095 in TEM stock By Investing.com
Tempus AI CFO James Rogers sold 11,529 shares of Class A Common Stock for $634,095 on June 25, 2026, pursuant to a Rule 10b5-1 trading plan. Despite the sale, which occurred at $55.0 per share, the stock has since risen to $58.28, yielding a 20% return over the past week, though InvestingPro suggests it might be overvalued. Mr. Rogers retains 114,866 shares, and the company is actively involved in new research collaborations and software validations.
Tempus AI director Jennifer Doudna sells $147,015 in stock
Tempus AI director Jennifer Doudna sold 2,673 shares of Class A Common Stock for $147,015 on June 25, 2026, as part of a Rule 10b5-1 trading plan. The stock price has since increased by 19.95%, though InvestingPro data suggests it may be overvalued. This transaction follows several key developments for Tempus AI, including research collaborations, a software validation study, and a new digital pathology consortium, with Canaccord Genuity maintaining a "Buy" rating and an $80 price target.
Tempus AI CFO James Rogers sells $634,095 in TEM stock By Investing.com
Tempus AI CFO James Rogers sold 11,529 shares of the company's Class A Common Stock for $634,095 on June 25, 2026, pursuant to a Rule 10b5-1 trading plan. Despite the stock's recent 20% return, InvestingPro data suggests it may be overvalued. In other news, Tempus AI has initiated research collaborations, validated FDA-cleared software, and launched a digital pathology consortium.
Tempus AI director Jennifer Doudna sells $147,015 in stock By Investing.com
Tempus AI director Jennifer Doudna sold 2,673 shares of Class A Common Stock for $147,015 on June 25, 2026, as part of a Rule 10b5-1 trading plan. Despite the sale, the stock has seen a significant surge, though it is considered overvalued by InvestingPro. In other news, Tempus AI is actively involved in significant research collaborations, including one with Angiosarcoma Awareness, Inc., and has launched a digital pathology open-source consortium, while analysts maintain a "Buy" rating on the stock.
Tempus AI (TEM) CFO sells 11,529 shares under Rule 10b5-1 plan
Tempus AI, Inc.'s Chief Financial Officer, James William Rogers, reported an open-market sale of 11,529 shares of Class A Common Stock at $55.00 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 11, 2025. Following the sale, Rogers directly holds 114,866 shares of the company.
Tempus AI (TEM) director sells 2,673 shares under 10b5-1 plan
Tempus AI director Jennifer A. Doudna reported an open-market sale of 2,673 shares of Class A Common Stock at $55.00 per share on June 25, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. Following the sale, Doudna directly holds 25,942 shares of the company's common stock.
Tempus AI (NASDAQ: TEM) insiders report multi-holder Class A sales
A recent SEC Form 144 filing indicates that several insiders at Tempus AI (NASDAQ: TEM) have reported proposed sales of Class A Common Stock. The filing details multiple transactions from April to May 2026, including sales by Eric Lefkofsky and related entities Blue Media, LLC and Gray Media, LLC, with specified share amounts and dollar proceeds. These sales primarily involve shares acquired through stock compensation and direct investment.
Tempus AI CFO James Rogers sells $634,095 in TEM stock
Tempus AI's CFO, James Rogers, sold 11,529 shares of the company's Class A Common Stock for $634,095 on June 25, 2026, as part of a Rule 10b5-1 trading plan. Despite the sale, the stock has seen a 20% return in the past week, though InvestingPro data suggests it may be overvalued. Rogers still holds 114,866 shares, and the company recently announced research collaborations and received a "Buy" rating from Canaccord Genuity.
TEM Forecast — Price Target — Prediction for 2027
This article provides a forecast for Tempus AI, Inc. Class A (TEM) stock, including analyst price targets and predictions for 2027. It details the current stock price, recent performance, general market capitalization, and historical highs and lows. The report also addresses common questions regarding the company's financial reports, earnings, revenue, dividends, employee count, and EBITDA.
Tempus AI, Inc. Class A Actuals & Estimates (NASDAQ:TEM)
This article provides an overview of Tempus AI, Inc. (NASDAQ: TEM) stock performance, financial estimates, and analyst forecasts. It includes current stock price, market capitalization, volatility, and details on past earnings reports and upcoming earnings dates. The article also addresses frequently asked questions about investing in Tempus AI, Inc. stock.
TEM Forecast — Price Target — Prediction for 2027
This article provides a forecast for Tempus AI, Inc. Class A (TEM) stock, including its price target, analyst ratings, and financial data. It highlights that the 15 analysts offering 1-year price forecasts estimate a maximum of 1,745.20 MXN and a minimum of 610.82 MXN for TEM. The article also covers recent stock performance, market capitalization, earnings, revenue, and EBITDA.
Alethea Capital Management LLC Makes New Investment in Tempus AI, Inc. $TEM
Alethea Capital Management LLC has made a new investment in Tempus AI, Inc. (NASDAQ:TEM), purchasing over 31,500 shares worth approximately $1.86 million, making it the 7th largest holding in their portfolio. This comes despite significant insider selling from Tempus AI executives, including CEO Eric P. Lefkofsky, totaling over $26 million in the last three months. Tempus AI exceeded Q1 earnings and revenue expectations, yet analysts maintain a mixed "Hold" rating with an average target price of $68.64.
Tempus AI, Inc. (NASDAQ:TEM) Given Average Recommendation of "Hold" by Brokerages
Tempus AI (NASDAQ:TEM) has received an average "Hold" recommendation from 15 brokerages, with an average 12-month price target of $68.64. The company recently reported Q1 revenue of $348.12 million, beating estimates, and EPS of -$0.13, also surpassing expectations, though it remains unprofitable. Insider sales were noted from CEO Ryan Fukushima and CFO James William Rogers, primarily to cover tax withholding related to equity awards.
Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Recommendation of "Hold" from Brokerages
Tempus AI, Inc. (NASDAQ:
Tempus AI, Inc. Class A Trade Ideas — XETR:F3M
This article provides trade ideas and technical analysis for Tempus AI, Inc. (XETR:F3M), focusing on key support and resistance levels. It outlines bullish and bearish scenarios based on price movements around 76.60 (support) and 77.30 (resistance), noting a double top pattern indicates a bearish leaning. Additionally, it includes various long-term analyses and options plays from multiple contributors, highlighting potential targets and risks for the stock.
Tempus AI (NASDAQ:TEM) Trading Up 9.3% - Time to Buy?
Tempus AI (NASDAQ:TEM) saw its shares rise 9.3% in mid-day trading, though with lower-than-average volume. The company recently beat earnings expectations with a smaller loss and significant revenue growth, despite still operating with negative margins. Analyst ratings are mixed, with some bullish price target increases but an overall "Hold" consensus and an average target price of $68.64.
Tempus AI (TEM) director Epstein sells 250 shares in pre-planned trade
David R. Epstein, a director at Tempus AI (TEM), sold 250 shares of Class A Common Stock at $49.40 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 27, 2024. Following this transaction, Epstein directly holds 31,464 shares. The sale is considered routine and relatively small compared to his total holdings, with no derivative exercises or complex instruments reported.
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
Tempus AI, Inc. announced the launch of an open-source digital pathology IMS Consortium with Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center as founding academic members. The consortium aims to democratize and standardize digital pathology by developing an open-source platform and viewer, with Tempus open-sourcing its existing Paige Image Management System. This initiative seeks to enhance patient care, optimize tissue utilization, and advance AI integration in clinical practice.
Canaccord Genuity Sticks to Their Buy Rating for Tempus AI, Inc. Class A (TEM)
Canaccord Genuity analyst Kyle Mikson CFA reiterated a Buy rating on Tempus AI, Inc. Class A (TEM) with a price target of $80.00. This comes as Tempus AI reported a quarterly revenue of $348.12 million for the quarter ending March 31, despite a GAAP net loss of $125.92 million. Other analysts from Guggenheim and Stifel Nicolaus also weighed in on the stock.
Tempus AI launches digital pathology open-source consortium By Investing.com
Tempus AI has launched a digital pathology open-source consortium with Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center as founding academic members. This initiative aims to develop an open-source digital pathology platform and viewer, expanding on Tempus's existing Paige Image Management System. The move comes as Tempus, despite being valued at $8.9 billion and showing significant revenue growth, remains unprofitable and its stock is considered overvalued by InvestingPro.
TEM - Tempus AI Inc Stock Price and Quote
This article provides comprehensive stock information for Tempus AI Inc (TEM), including its current stock price, financial data, insider transactions, and analyst ratings. It highlights recent share sales by CEO Eric Lefkofsky and affiliates, ongoing research collaborations, and various business developments in AI-driven precision medicine. The data emphasizes key financial metrics, stock performance, and recent news impacting the company.
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM) and Incyte (INCY)
This article provides analyst insights on three healthcare companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM), and Incyte (INCY). Eli Lilly received a Strong Buy consensus with a $1267.57 average price target, while Tempus AI, Inc. Class A has a Moderate Buy consensus with a $66.08 average price target. Incyte also has a Moderate Buy consensus with an average price target of $108.29.
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM) and Incyte (INCY)
This article provides an overview of recent analyst ratings for three healthcare companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM), and Incyte (INCY). Analysts from Barclays, William Blair, Citi, and TD Cowen have offered insights, with price targets and consensus ratings ranging from Strong Buy to Hold, indicating varying levels of optimism for these stocks.
Tempus AI CEO Eric Lefkofsky sells $7.76m in stock
Tempus AI CEO Eric Lefkofsky sold Class A Common Stock worth $7.76 million on May 27, 2026, through entities he manages, under a pre-arranged 10b5-1 trading plan. The shares were sold at weighted average prices between $46.17 and $46.89. This comes as Tempus AI, an AI healthcare company valued at $9.2 billion, shows strong revenue growth and recently received FDA approval for its xT CDx platform and expanded its Next platform.
Tempus AI CEO Eric Lefkofsky sells $7.76m in stock By Investing.com
Tempus AI CEO Eric P. Lefkofsky sold 166,250 shares of Class A Common Stock for a total of $7.76 million on May 27, 2026, at weighted average prices between $46.17 and $46.89. The transactions were conducted through entities managed by him and were part of a Rule 10b5-1 trading plan. Despite profitability challenges, the AI healthcare company, valued at $9.2 billion, has shown a 70% revenue growth, and its stock is currently trading at $50.46.
Lefkofsky entities sell 166K Tempus AI (TEM) shares under 10b5-1 plan
Entities linked to Tempus AI CEO and Chairman, Eric Lefkofsky, specifically Blue Media, LLC and Gray Media, LLC, sold a combined 166,250 shares of Class A Common Stock on May 27, 2026. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted in March 2025 at weighted-average prices around $45-$47 per share. Despite these sales, the entities retain substantial holdings in Tempus AI, indicating routine portfolio management rather than a strategic shift.
Tempus AI CEO Eric Lefkofsky sells $7.76m in stock
Tempus AI, Inc. CEO Eric P. Lefkofsky sold Class A Common Stock worth $7,763,312 on May 27, 2026, through entities he manages, under a Rule 10b5-1 trading plan. The shares were sold at weighted average prices between $46.17 and $46.89, while the stock currently trades at $50.46. Despite a recent 9.3% gain, InvestingPro suggests the company might be overvalued, although it exhibits impressive 70% revenue growth with a $9.2 billion valuation, alongside ongoing profitability challenges.
Tempus AI (TEM) insiders sell Class A shares totaling hundreds of thousands in proceeds
Tempus AI (TEM) has reported multiple insider sales of Class A Common stock via Form 144 filings. Notable sales include Eric Lefkofsky selling 22,335 shares for over $984,000, and Blue Media, LLC selling two blocks of 133,000 shares each for total proceeds exceeding $12.9 million. These transactions are routine Rule 144 filings, detailing open-market transactions by insiders and affiliated entities.
Tempus AI (TEM) director receives 5,913 RSUs vesting in 2027
Tempus AI director Nadja West was granted 5,913 Class A common shares in the form of restricted stock units (RSUs) as compensation, increasing her direct holdings to 37,981 shares. These RSUs will vest in full on the earlier of the company’s 2027 annual meeting of stockholders or May 21, 2027, contingent upon her continuous service with Tempus AI. This transaction was reported in a Form 4 filing and does not involve any cash payment from West.
Director at Tempus AI (TEM) granted 5,913 RSUs vesting by 2027 meeting
Tempus AI director David R. Epstein was granted 5,913 restricted stock units (RSUs) of Class A common stock for no cash cost, increasing his directly held position to 31,714 shares. These RSUs will vest in full on the earlier of the company's 2027 annual stockholder meeting or May 21, 2027, provided he continues his service with the company. This equity compensation aligns the director's interests with those of shareholders.
Director Jennifer Doudna receives 5,913-share RSU award at Tempus AI (TEM)
Tempus AI (TEM) director Jennifer Doudna has been granted 5,913 shares of Class A common stock as a restricted stock unit (RSU) award. This award is a routine, non-cash compensation, increasing her direct holdings to 28,615 shares. The RSUs will vest in full either at the company's 2027 annual stockholder meeting or on May 21, 2027, provided her continuous service as a director.
Tempus AI (TEM) director awarded 5,913 RSUs vesting by 2027 meeting
Tempus AI (TEM) director Frederick Wayne A.I. was granted 5,913 shares of Class A Common Stock as restricted stock units with a $0.00 purchase price. These RSUs will fully vest on the earlier of the company’s 2027 annual stockholder meeting or May 21, 2027, provided he maintains continuous service. Following this award, his direct holdings in Tempus AI total 30,749 shares.
Tempus AI (TEM) director Theodore Leonsis receives 5,913-share RSU grant
Tempus AI director Theodore Leonsis was granted 5,913 restricted stock units (RSUs) as equity compensation, increasing his direct holdings to 21,424 shares. The RSUs, valued at $0.00 per share, will fully vest on the earlier of the company's 2027 annual stockholder meeting or May 21, 2027, contingent on his continuous service. Additionally, 66,756 shares are held indirectly through the Theodore J. Leonsis Revocable Trust.
Tempus AI (TEM) director Barris granted 5,913 RSUs vesting in 2027
Tempus AI (TEM) director Peter J. Barris was granted 5,913 Restricted Stock Units (RSUs) as an equity award. These RSUs, which have an award price of $0.00 per share, will vest in full on the earlier of the company's 2027 annual stockholders meeting or May 21, 2027, provided Barris maintains continuous service. Following this grant, Barris directly holds 121,424 shares of Tempus AI Class A Common Stock.
Tempus AI (TEM) director Eric Belcher receives 5,913-share RSU grant
Tempus AI (TEM) director Eric Belcher was granted 5,913 restricted stock units (RSUs) of Class A common stock at a price of $0.00 per share. These RSUs will vest in full either at the company's 2027 annual stockholder meeting or on May 21, 2027, whichever comes earlier, contingent on his continuous service. Following this grant, Belcher directly holds 21,424 Class A shares and indirectly holds 14,033 shares through Nob Hill Ventures LLC.
Tempus AI (TEM) director Scott Gottlieb receives 5,913 restricted stock units
Tempus AI director Scott Gottlieb has been awarded 5,913 restricted stock units (RSUs) as part of an equity compensation package. These RSUs, valued at $0.00 per share, will fully vest on the earlier of the company’s 2027 annual stockholder meeting or May 21, 2027, contingent upon his continuous service. Following this grant, Gottlieb directly holds 40,749 shares of Tempus AI Class A common stock.
Tempus AI (NASDAQ: TEM) investors choose 3-year say-on-pay cycle
Tempus AI (NASDAQ: TEM) shareholders, during their 2026 Annual Meeting, elected nine directors to serve until the 2027 annual meeting and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. A significant majority of 191,972,032 votes favored holding advisory "say-on-pay" votes every three years, a frequency the board has adopted. Class A shares carry one vote, while Class B shares have 30 votes each.
Tempus AI (TEM) Diagnostics CEO sells 1,580 shares for RSU tax withholding
Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI (TEM), sold 1,580 shares of Class A common stock for a weighted average price of $44.07 per share. This transaction was not a discretionary sale but a mandated "sell to cover" to fulfill statutory tax withholding obligations related to the vesting of restricted stock units. Following this sale, Schoenherr directly holds 107,029 shares of Tempus AI.
Tempus AI (TEM) executive logs 13,550-share tax sell-to-cover transaction
Tempus AI (TEM) executive Fukushima Ryan sold 13,550 shares of Class A Common Stock at a weighted average price of $44.07 per share. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations from restricted stock unit vesting, not a discretionary sale. Following the transaction, Ryan directly holds 603,558 shares and indirectly holds 211,047 shares through his spouse.
Tempus AI (TEM) CAO executes mandatory sell-to-cover for RSU taxes
Tempus AI's Chief Accounting Officer, Ryan M. Bartolucci, sold 4,116 shares of Class A Common Stock on May 19, 2026, at a weighted average price of $44.07 per share. This sale was a mandatory "sell to cover" transaction to satisfy tax withholding obligations on vested restricted stock units, not a discretionary sale. Following this transaction, Bartolucci directly holds 74,041 shares of Tempus AI Class A Common Stock.
Tempus AI (TEM) CFO’s mandated share sale covers RSU tax obligations
Tempus AI's Chief Financial Officer, James William Rogers, sold 10,853 shares of Class A Common Stock on May 19, 2026, at a weighted average price of $44.07 per share. This mandatory sale was executed to cover statutory tax withholding obligations stemming from the vesting of restricted stock units (RSUs) and was not a discretionary decision by the executive. Following the transaction, Rogers directly holds 126,395 shares of Tempus AI Class A Common Stock.
Tempus AI (TEM) CEO Lefkofsky sells 22,335 shares to cover RSU taxes
Tempus AI (TEM) CEO Eric P. Lefkofsky sold 22,335 Class A shares at a weighted average price of $44.07 per share on May 19, 2026. This transaction was a "sell to cover" to meet statutory tax withholding obligations related to the vesting of restricted stock units (RSUs) and was not a discretionary sale. Following the sale, Lefkofsky directly holds 2,230,721 Class A shares and maintains significant indirect holdings through various entities.
Tempus AI (TEM) legal chief’s non-discretionary tax sell-to-cover trade
Tempus AI's EVP and Chief Legal Officer, Andrew Polovin, sold 8,703 shares of Class A Common Stock at a weighted average price of $44.07 per share. This transaction was a non-discretionary "sell to cover" sale to fund statutory tax withholding obligations related to vested restricted stock units, as mandated by the company’s equity plan. Post-sale, Polovin directly holds 128,215 shares of Tempus AI Class A Common Stock.
ETFs Investing in Tempus AI, Inc. Class A Stocks
This article lists various ETFs that currently hold Tempus AI, Inc. Class A stock, providing details such as market value, weight in the fund, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover a range of investment strategies, including active and passive management, and focus on different market segments like total market, small-cap, health care, and artificial intelligence themes. The information aims to help investors identify funds that offer exposure to Tempus AI, Inc. Class A stocks with diversified opportunities and reduced risk.
Price to sales ratio of Tempus AI, Inc. Class A – HAM:F3M
The article displays the price to sales ratio for Tempus AI, Inc. Class A (HAM:F3M) on TradingView. It provides financial overview, news, community insights, and forecasts for the company. The page also lists various services and resources offered by TradingView, including market data, charting tools, and educational content.
Tempus AI, Inc. Class A Trade Ideas — HAM:F3M
This article compiles several trade ideas and analyses for Tempus AI (HAM:F3M, NASDAQ:TEM) from various traders on TradingView. The perspectives range from pre-market breakdowns and multi-timeframe analysis to options strategies, fundamental growth assessments, and technical setups like breakouts, retracements, and potential short or long scenarios. Many analysts highlight Tempus AI's strong revenue growth, substantial clinical data assets, and strategic partnerships as key drivers, while also discussing critical price levels and potential entry/exit points for trading.
Cash per share of Tempus AI, Inc. Class A – HAM:F3M
This article provides financial information for Tempus AI, Inc. Class A (HAM:F3M), specifically focusing on its cash per share data. It includes a basic overview of the company's financial performance by period, value, and change, as presented on TradingView. The content also lists various data providers and copyright notices.
